Business
Revuforj® (revumenib) Named Best New Drug at the Scrip Awards 2025
NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer
About this update from Syndax Pharmaceuticals, Inc.
[{"type":"text","content":"NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Revuforj® (revumenib) was named Best New Drug at the Scrip Awards 2025, held by Citeline. The Best New Drug Award recognizes excellence in pharmaceutical development and the drug that represents the best therapeutic advance in its area. Revuforj is a first-in-class menin inhibitor that was FDA approved in November 2024 for the treatment of relapsed or refractory (R/R) acute leukemia with a KMT2A translocation as determined by an FDA-authorized test in adult and pediatric patients one year and older. In October 2025, Revuforj was approved by the FDA for the treatment of R/R acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation in adult and pediatric patients one year and older who have no satisfactory alternative treatment options. “It is an honor to receive this prestigious award from Scrip in recognition of the groundbreaking science behind Revuforj and the tremendous promise it holds for patients with menin-dependent acute leukemia,” said Michael A. Metzger, Chief Executive Officer. “Receiving this award on the heels of the recent approval of Revuforj for a second patient population is a testament to Syndax’s leadership in menin inhibition and deep commitment to patient care.” The Scrip Awards are recognized as one of the most prestigious awards for the biopharma industry. The Awards honor the innovations, breakthroughs, and contributions shaping the global biopharma landscape. About Revuforj® (revumenib) Revuforj (revumenib) is an oral, first-in-class menin inhibitor that is FDA approved for the treatment of relapsed or refractory (R/R) acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation as determined by an FDA-authorized test in adult and pediatric patients one year and older. Revuforj is also indicated for the treatment of R/R acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation in adult and pediatric patients one year and older who have no satisfactory alternative treatment options. Multiple trials of revumenib are ongoing or planned across the treatment landscape, including in combination with standard of care therapies in newly diagnosed patients with NPM1m or...